PETMED EXPRESS INC

Trading Arrangements

During the fourth quarter ended March 31, 2025, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted, modified, orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Trade Name Impairment

As part of the Company’s impairment testing conducted in connection with the preparation of the financial statements included in this Annual Report on Form 10-K, the reduction in actual and forecasted revenues related to the Company’s trade name led the Company to conclude that it was more likely than not that the fair value of the trade name was less than its book value. As result of the Company’s quantitative impairment test, the Company concluded there was a $1.2 million impairment of its trade name. For additional information regarding this impairment charge, see Note 2 (Summary of Significant Accounting Principles) to our Consolidated Financial Statements in included in this Annual Report on Form 10-K under the caption “Intangible Assets.”

2025 Annual Meeting of Shareholders

The board of directors of the Company (the “Board”) has determined that the Company’s 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”) will be held virtually on January 21, 2026. More detailed information regarding the 2025 Annual Meeting will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A to be filed with the Securities and Exchange Commission (“SEC”). Because the date of the 2025 Annual Meeting date has been changed by more than 30 days from the anniversary date of the Company’s 2024 annual meeting of shareholders (the “2024 Annual Meeting”), in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is hereby informing shareholders of such change. In addition, because the 2025 Annual Meeting will be held more than 30 days from the anniversary date of the 2024 Annual Meeting, the deadlines set forth in the proxy statement for the 2024 Annual Meeting for the submission of shareholder proposals pursuant to Rule 14a-8 of the Exchange Act and director nominations pursuant to the Company’s proxy access rights, in each case for consideration at the 2025 Annual Meeting, no longer apply. Further, because the date of the 2025 Annual Meeting will be held more than 60 days from the anniversary date of the 2024 Annual Meeting, the deadlinesset forth in the proxy statement for the 2024 Annual Meeting for shareholders to submit a notice of a proposal outside the processes of Rule 14a-8 of the Exchange Act and a notice of proposed director nominations, in each case for consideration at the 2025 Annual Meeting, no longer apply.

In order for a shareholder proposal, submitted solely pursuant to Rule 14a-8 of the Exchange Act, to be considered timely for inclusion in the Company’s proxy statement and form of proxy for the 2025 Annual Meeting, such proposal must be received by the Company by October 24, 2025. Therefore, in order for a shareholder to submit a proposal for inclusion in the Company’s proxy materials for the 2025 Annual Meeting, the shareholder must comply with the requirements set forth in Rule 14a-8, including, without limitation, with respect to the subject matter of the proposal, and must deliver the proposal and all required documentation to the Company at its principal executive offices at the address set forth below no later than October 24, 2025. The public announcement of an adjournment or postponement of the date of the 2025 Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8. Any such shareholder proposals should be mailed to the Company at the following address: PetMed Express, Inc., 420 South Congress Avenue, Delray Beach, FL 33445, Attention: Corporate Secretary.

The Company’s Third Amended and Restated Bylaws (the “Bylaws”) provide shareholders with a proxy access right that permits a shareholder, or group of up to 20 shareholders, owning an aggregate of at least 3% of the Company’s outstanding common stock continuously for at least three years to nominate and include in the Company’s proxy materials director nominees constituting up to the greater of two individuals or 20% of the Board, provided that the shareholder(s) and the nominee(s) satisfy the requirements specified in the Bylaws. A shareholder who intends to nominate and include in the Company’s proxy materials proxy access director nominees must cause a notice of nominations of such proxy access nomineesto be received by the Company at the same address provided above no later than the close of business on October 24, 2025, which is the 10th day following the first public disclosure by the Company of the date of the 2025 Annual Meeting, and must comply with the other requirements of the Bylaws, including, but not limited to, the requirements with respect to the form and content of a proxy access notice of nominations. Any notice of proxy access nominations received after such date will be considered untimely. In no event shall any adjournment or postponement of the 2025 Annual Meeting, or the announcement thereof, commence a new time period for the giving of such notice of proxy access nominations.

Because the date of the 2025 Annual Meeting will be held more than 60 days from the anniversary date of the 2024 Annual Meeting, to be timely in accordance with the Bylaws, shareholders intending to submit a proposal outside the processes of Rule 14a-8 of the Exchange Act or a proposed director nomination, in each case for consideration at the 2025

Annual Meeting, must cause a notice of such proposal and/or proposed director nomination to be received by the Company at the same address provided above no later than the close of business on October 24, 2025, which is the 10th day following the first public disclosure by the Company of the date of the 2025 Annual Meeting. In addition to satisfying the requirements under the Bylaws, shareholders who intend to solicit proxies in support of director nominees other than the Company’s nominees at the 2025 Annual Meeting must provide notice to the Company’s Corporate Secretary no later than October 24, 2025 in accordance with Rule 14a-19 of the Exchange Act, also known as the universal proxy rule. In no event shall any adjournment or postponement of the 2025 Annual Meeting, or the announcement thereof, commence a new time period for the giving of such notices. Such notices must also comply with all other requirements set forth in the Bylaws (which, in the case of proposed director nominations, also requires the information required by Rule 14a-19 of the Exchange Act), the Exchange Act, and other applicable laws.